Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations

Abstract Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have improved the prognosis of mutant lung cancer; however, the clinical application value of TKIs for nonclassical EGFR mutation is unclear, especially for patients with rare uncommon mutations. Methods A...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Teng Li, Shouzheng Wang, Jianming Ying, Yan Wang, Xingsheng Hu, Xuezhi Hao, Ziyi Xu, Puyuan Xing, Junling Li
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2021-11-01
Schriftenreihe:	Thoracic Cancer
Schlagworte:	afatinib non‐small cell lung cancer uncommon mutation
Online-Zugang:	https://doi.org/10.1111/1759-7714.14156
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!